Avalyn Pharma to Present at Morgan Stanley Healthcare Conference…

Event summary

Avalyn Pharma will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, from 1:50-2:25 p.m. ET.
The company is advancing inhaled therapies for rare respiratory diseases, including AP01 (pirfenidone) and AP02 (nintedanib) in Phase 2 trials.
Avalyn's AP03 program combines pirfenidone and nintedanib in a single inhaled formulation.
The live webcast and archived recording will be available on Avalyn's Investor Relations page.

The big picture

Avalyn Pharma's participation in the Morgan Stanley conference underscores its push to establish inhaled therapies as a new standard in treating pulmonary fibrosis. The company's focus on lung-targeted antifibrotic treatments aligns with broader industry trends toward precision medicine and reducing systemic side effects. Success in its ongoing trials could position Avalyn as a key player in the rare respiratory disease market.

What we're watching

Clinical Progress: How the Phase 2b MIST and Phase 2 AURA trials will impact Avalyn's pipeline momentum.
Market Positioning: Whether Avalyn can differentiate itself in the competitive pulmonary fibrosis treatment landscape.
Investor Sentiment: The pace at which investor interest grows following the conference presentation.